Credit: A Health Blog.

Researchers at University College London (UCL) have developed a new artificial intelligence (AI) technology, called the SuStaIn algorithm, to identify and differentiate various dementias, including Alzheimer’s disease.

The machine learning algorithm works by analysing patient MRI scans and can automatically disentangle varying patterns of progression in different patients.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The new technology is also expected to enable the detection of individuals who may respond best to different treatments.

"The machine learning algorithm works by analysing patient MRI scans and can automatically disentangle varying patterns of progression in different patients."

When tested, the SuStaIn algorithm has reportedly identified three separate subtypes of Alzheimer’s disease.

The researchers said that early detection of the subtypes and the use of non-invasive MRI scanning provides a better chance of determining the best treatment for patients.

UCL Centre for Medical Image Computing researcher Alexandra Young said: “Individuals might present with similar symptoms to each other, but using SuStaIn we can find that they belong to different subgroups.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

“This allows us to predict more accurately how their disease will progress and diagnose it earlier.”

The team noted that drugs fail in clinical trials for Alzheimer’s disease because a variety of very different patients are recruited and tested for a single treatment.

Centre for Medical Image Computing professor Daniel Alexander added: “A treatment with a strong effect on a particular subgroup of patients may show no overall effect on the full population so fail the drug trial.

“SuStaIn provides a way to show treatment effects on distinct subgroups, potentially expediting treatments to market.”

Currently, the researchers are working on expanding the use of the machine learning SuStaIn algorithm to additional diseases.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
SC MEDICA’s minimally invasive, radiation free spinal facet fixation system, FFX® is transforming spinal pain management and improving outcomes for surgeons and patients alike. Learn how SC MEDICA’s award-winning technology is redefining standards in facet joint pain treatment.

Discover the Impact